PlatformQ Health partnered with the American Macular Degeneration Foundation, Opthalmology360, and BroadcastMed to produce a 4-part CME activity called, “Intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) Therapies: Updates in Diabetic Eye Diseases, Retinal Vein Occlusion and Age-Related Macular Degeneration.”

This series launched live on Tuesday, November 17th on the digital education channel, ClinicalSeriesLive, through which the program is anticipated to reach thousands of healthcare professionals. The CME series is currently available on-demand, allowing HCPs who missed the live event to watch at any time, and live participants the opportunity to re-watch the activities as needed.

As the COVID-19 pandemic continues to change health care delivery in the US, these activities were designed to equip clinicians to navigate those changes in their care of patients with retinal diseases who are in need intravitreal anti-VEGF therapy. These patients must adhere to their treatment schedules or risk vision deterioration or loss, including patients with diabetic retinopathy (DR), diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), and retinal vein occlusion (RVO). As therapies for these disorders continue to make incremental improvements to minimize treatment burden and improve outcomes, clinicians who provide anti-VEGF therapy need to be kept up to date with the latest data and best practices.

During these activities Dr. Jeffrey Heier and Dr. Charles Wykoff, along with patient advocate Matthew Levine discuss strategies to adapt eye care and anti-VEGF injections to the evolving COVID-19 environment, while appropriately incorporating evidence-based treatment advances into patient care.

Want to learn more about each session’s learning objectives?

Module One: Anti-VEGF Injections in the Era of COVID-19: Implications for Patients

• Discuss the potential impact of COVID-19 pandemic on the timely delivery of intravitreal anti-VEGF and vision monitoring
• Review strategies for maintaining optimal therapy for patients needing intravitreal anti-VEGF injections, while reducing COVID-19 transmission to patients, clinicians, and staff
• Define strategies to prepare patients for clinic visits under COVID-19 policies

Module Two: Management of the Diabetic Retinopathy: What is New?

• Review how the introduction of anti-VEGF therapy has affected the natural history of DR
• Highlight limitations of technologies and severity scales currently used to monitor disease progression
• Review recent clinical trials data and subsequent subanalyses from Diabetic Retinopathy Clinical Research Network (DRCR.net) documenting the impact of anti-VEGF therapy on DR management

Module Three: Evolution of Treatment Paradigm for AMD: Evaluating the Data from Clinical and Real-life Experience

• Discuss the place of q12w dosing strategy in current treatment paradigms for AMD
• Analyze emerging data indicating that every eye is an anti-VEGF responder if diagnosed early and treated
• Discuss the place of new and emerging treatment strategies and paradigms for nAMD

Module Four: Treatment Choices for Retinal Vein Occlusion (RVO)

• Discuss clinical data with anti-VEGF, steroid, and laser therapies and evolving injections paradigms for anti-VEGF
• Identify cases when steroid or PRP can be used in the first line management of RVO
• Apply AAO recent Preferred Practice Patterns in the management of patients with RVO

Check out each session on-demand on ClinicalSeriesLive today! These activities are supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Have questions about this educational series or want to learn more about how PlatformQ Health is delivering impactful education to HCPs and patients? Email us at digital@platformq.com.